JP2018521139A - 急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物 - Google Patents

急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物 Download PDF

Info

Publication number
JP2018521139A
JP2018521139A JP2018521707A JP2018521707A JP2018521139A JP 2018521139 A JP2018521139 A JP 2018521139A JP 2018521707 A JP2018521707 A JP 2018521707A JP 2018521707 A JP2018521707 A JP 2018521707A JP 2018521139 A JP2018521139 A JP 2018521139A
Authority
JP
Japan
Prior art keywords
film
midazolam
unit dosage
forming substance
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521139A5 (cg-RX-API-DMAC7.html
Inventor
シェーグレン，クリステル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swipp AB
Original Assignee
Swipp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swipp AB filed Critical Swipp AB
Publication of JP2018521139A publication Critical patent/JP2018521139A/ja
Publication of JP2018521139A5 publication Critical patent/JP2018521139A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018521707A 2015-07-16 2016-07-15 急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物 Pending JP2018521139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570475 2015-07-16
DKPA201570475 2015-07-16
PCT/EP2016/066860 WO2017009446A1 (en) 2015-07-16 2016-07-15 Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action

Publications (2)

Publication Number Publication Date
JP2018521139A true JP2018521139A (ja) 2018-08-02
JP2018521139A5 JP2018521139A5 (cg-RX-API-DMAC7.html) 2019-07-18

Family

ID=53785375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521707A Pending JP2018521139A (ja) 2015-07-16 2016-07-15 急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物

Country Status (6)

Country Link
US (2) US20180221384A1 (cg-RX-API-DMAC7.html)
EP (1) EP3322402B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018521139A (cg-RX-API-DMAC7.html)
CN (1) CN108024952A (cg-RX-API-DMAC7.html)
ES (1) ES2738652T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017009446A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513303A (ja) * 2021-03-04 2024-03-25 エルテーエス ローマン テラピー－ジステーメ アーゲー 経口薄フィルム

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4392015A1 (en) 2021-08-25 2024-07-03 Swipp Ab Oral film unit dosage form
WO2024180209A1 (en) 2023-03-01 2024-09-06 Swipp Ab Crystalline form of midazolam hydrochloride
EP4673122A1 (en) 2023-03-01 2026-01-07 Swipp Ab Oral film unit dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512402A (ja) * 1999-10-27 2003-04-02 アネスタ・コーポレーション 固溶体を用いる経口経粘膜薬剤投与形態
JP2007502823A (ja) * 2003-08-15 2007-02-15 キューエルティー・ユーエスエイ・インコーポレーテッド 接着性および生体侵食性の経粘膜薬物送達システム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
JP2006515333A (ja) * 2003-03-26 2006-05-25 ザ プロクター アンド ギャンブル カンパニー 改善されたフィルム強度及び安定性を有する急速溶解性食用フィルム組成物
CN1830447B (zh) * 2006-04-02 2011-03-16 岳振江 马来酸咪达唑仑口服膜剂及其制备方法
AU2010313785C1 (en) * 2009-10-30 2019-04-11 Ix Biopharma Ltd Fast dissolving solid dosage form
CN102892815B (zh) * 2010-03-26 2016-05-18 陶氏环球技术有限责任公司 熔体挤出的膜

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512402A (ja) * 1999-10-27 2003-04-02 アネスタ・コーポレーション 固溶体を用いる経口経粘膜薬剤投与形態
JP2007502823A (ja) * 2003-08-15 2007-02-15 キューエルティー・ユーエスエイ・インコーポレーテッド 接着性および生体侵食性の経粘膜薬物送達システム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BR J CLIN PHARMACOL, vol. 46, JPN6020019907, 1998, pages 203 - 206, ISSN: 0004283883 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513303A (ja) * 2021-03-04 2024-03-25 エルテーエス ローマン テラピー－ジステーメ アーゲー 経口薄フィルム
JP7738665B2 (ja) 2021-03-04 2025-09-12 エルテーエス ローマン テラピー－ジステーメ アーゲー 経口薄フィルム

Also Published As

Publication number Publication date
CN108024952A (zh) 2018-05-11
US20200306260A1 (en) 2020-10-01
ES2738652T3 (es) 2020-01-24
US20180221384A1 (en) 2018-08-09
WO2017009446A1 (en) 2017-01-19
EP3322402A1 (en) 2018-05-23
EP3322402B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
JP5600747B2 (ja) 口腔内分散性製剤
JP3221880B2 (ja) 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用
US12128027B2 (en) N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
CN109431966B (zh) 依达拉奉药物组合物
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
US20200306260A1 (en) Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action
TW202228682A (zh) 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
KR20180127951A (ko) 바레니클린 서방성 제제 및 이의 제조 방법
JP2003520252A (ja) テルビナフィン含有医薬組成物
EP3949955A1 (en) Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
RU2362548C1 (ru) Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
CN105193764A (zh) 一种阿戈美拉汀固体分散体及其制备方法
JP2012031164A (ja) フィルム状製剤
CN118615260A (zh) 一种吡仑帕奈口溶膜的药物组合物及其制备方法
EA010372B1 (ru) Диспергируемая во рту фармацевтическая композиция антитромботического соединения
CN100413504C (zh) 阿昔洛韦药物树脂生物粘附缓释液体制剂及其制备方法
JP7076579B2 (ja) シロリムスを含む、改善された含量均一性を有する薬剤学的製剤
JP5962161B2 (ja) 耳管開放症治療剤
EP4494634A1 (en) Esketamine liquid preparation and use thereof
JP3935539B2 (ja) フマル酸ケトチフェン含有医薬組成物
US20250339366A1 (en) An orodispersible tablet of rivaroxaban
JPH11501026A (ja) イソソルビド−５−モノナイトレートの使用
CN117159448A (zh) 一种氯雷他定口服凝胶制剂、制法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180308

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211102

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211109

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211119

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211130

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221129

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230110

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230124

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230124